DIABETIC NEPHROPATHY: LATEST GUIDELINES AND MANAGEMENT STRATEGIES

Botirova Nigina Akram qizi
TASHKENT MEDICAL ACADEMY

Introduction

In 2015, the International Diabetic Federation estimated that the prevalence of diabetes was 8.8% from ages 20 to 79 years affecting a population of approximately 440 million people. This is predicted to grow to over 550 million people by the year 2035 [i]. One of the most important clinical features of diabetes is its association with chronic tissue complications. A short-term increase in hyperglycemia does not result in serious clinical complications. The duration and severity of hyperglycemia is the major causative factor in initiating organ damage. Early morphological signs of renal damage include nephromegaly and a modified Doppler, but the degree of damage is best ascertained from proteinuria and Glomerular filtration rate (GFR). The average incidence of diabetic nephropathy is high (3% per year) during the first 10 to 20 years after diabetes onset. Typically, it takes 15 years for small blood vessels in organs like kidney, eyes and nerves to get affected. It is estimated that more than 20 and up to 40% of diabetic patients will develop chronic kidney disease (CKD), depending upon the population, with a significant number that develop end stage kidney disease (ESKD) requiring renal replacement therapies such as kidney transplantation. Incidentally, diabetes with no clinical sign of kidney damage during the initial 20 to 25 years is significantly less likely (1% a year) to cause major renal complication later in life.

Key words: Microalbuminuria, diabetic nephropathy, chronic kidney disease, glomerular filtration rate.

Diabetic nephropathy is the leading cause of end stage kidney disease, accounting for approximately 50 % of cases of end stage renal disease. Microalbuminuria is the earliest clinical manifestation of diabetic nephropathy. Microalbuminuria may progress to overt albuminuria, which is a hallmark of irreversible nephropathy and predicts progression of kidney disease. Many of the pathophysiological changes seen in the kidney in diabetic nephropathy result from prolonged hyperglycemia. The podocyte is one of the key targets in diabetic kidney disease and podocyte damage leads to foot process effacement and the development of proteinuria. While angiotensin converting enzyme inhibitors and angiotensin receptor blockers have long been used as the mainstay of treatment for diabetic nephropathy, targeted, effective new therapies are urgently needed.

Diabetic nephropathy (DN) is one of the most common and serious complications

of diabetes mellitus. It is the leading cause of end-stage renal disease (ESRD) worldwide. The condition is characterized by progressive kidney damage due to chronic hyperglycemia and other metabolic disturbances associated with diabetes. Early detection and proper management of diabetic nephropathy are crucial in preventing further renal decline and improving patient outcomes.

Diabetic nephropathy is a clinical syndrome characterized by the following[ii]:

Persistent albuminuria (>300 mg/d or >200 μg/min) that is confirmed on at least 2 occasions 3-6 months apart

Progressive decline in the glomerular filtration rate (GFR)

Elevated arterial blood pressure

This article provides an overview of the latest guidelines on the diagnosis, prevention, and treatment of diabetic nephropathy, based on recent research and recommendations from leading health organizations.

Pathophysiology of Diabetic Nephropathy

Diabetic nephropathy typically progresses through the following stages:

1. Hyperfiltration stage: Early in the disease, glomerular filtration rate (GFR) increases due to hyperglycemia.

2. Microalbuminuria: Small amounts of albumin begin to leak into the urine, which is one of the earliest signs of kidney damage.

3. Macroalbuminuria: The amount of albumin in the urine increases substantially as the damage worsens.

4. Declining GFR: Over time, GFR begins to decrease, leading to chronic kidney disease (CKD) and potentially ESRD.

The key mechanisms involved include glomerular hypertension, inflammation, oxidative stress, and the activation of the renin-angiotensin-aldosterone system (RAAS).

Diabetes leads to progressive structural alterations of the kidneys including extracellular matrix (ECM) accumulation in the mesangium, glomerular basement membrane, and tubulointerstitial tissue. The pathophysiology of diabetic nephropathy is complex and multifactorial. Poor glycemic control was previously considered the sole driving factor that drives diabetic nephropathy. However, some studies demonstrated variability in the development of renal complications despite comparable hyperglycemic control. For example, the Diabetes Control and Complications Trial (DCCT) showed that nearly 30% of type I diabetics and 25%–40% of type II diabetics develop nephropathy despite intensive glycemic control [iii]. Variations between ethnic groups also point to the significant role of genetic background. Relatives of African Americans on renal replacement therapy secondary to diabetic nephropathy are at fivefold risk of developing ESRD [iv]. Additionally, the incidence of ESRD per capita in African Americans, Hispanics, and Native Americans is significantly higher than the

white population [v]. The incidence of proteinuria among Pima Indians has also been increasing over the past 36 years. However, the incidence of progression to ESRD declined after 1990, possibly due to improved control of risk factors [vi]. A multicenter study in 10 Asian countries on type II diabetic patients of different ethnic groups showed nearly 40% prevalence rate of microalbuminuria, a worrisome marker for developing ESRD [vii]. Familial aggregation further supports the role of genetics in development of ESRD. A large population-based study showed that nearly 23% of incident dialysis patients had relatives with ESRD, with greater prevalence in African Americans compared to European Americans [viii]. Individuals with family history of ESRD were also more likely to have diabetes and obesity [ix].

2. Risk Factors for Diabetic Nephropathy

Several factors increase the risk of developing diabetic nephropathy:

- Duration of diabetes: The risk increases with the length of time a person has had diabetes.

- Poor glycemic control: Consistently high blood glucose levels accelerate kidney damage.

- Hypertension: High blood pressure further damages the kidneys and worsens the disease.

- Genetic predisposition: Certain genetic factors may increase susceptibility.

- Smoking: Smoking exacerbates kidney damage and accelerates progression toward ESRD.

- Dyslipidemia: Abnormal cholesterol levels are associated with an increased rate of kidney damage.

3. Diagnosis of Diabetic Nephropathy

Screening Recommendations

Early detection of diabetic nephropathy is crucial, as it allows for interventions that can slow or even halt disease progression. The following are the key screening recommendations:

- Type 1 diabetes: Annual screening should begin 5 years after the diagnosis of diabetes.

- Type 2 diabetes: Annual screening should start immediately upon diagnosis.

Diagnostic Tools

- Urine Albumin-to-Creatinine Ratio (UACR): This test measures the amount of albumin in the urine. Persistent microalbuminuria (30-300 mg/g) is a marker of early DN, while macroalbuminuria (>300 mg/g) indicates more advanced disease.

- Estimated Glomerular Filtration Rate (eGFR): This is used to assess the kidney's filtering capacity. A declining eGFR indicates worsening kidney function.

- Serum Creatinine: Elevated serum creatinine can indicate reduced kidney function, though it’s often used in combination with other metrics like eGFR.

4. Management of Diabetic Nephropathy

Glycemic Control

Tight glucose control is essential to slow the progression of diabetic nephropathy. The latest guidelines recommend:

- HbA1c target: Aim for an HbA1c of <7% for most patients, though individual targets may vary depending on the risk of hypoglycemia and other comorbidities.

- Newer glucose-lowering agents: Sodium-glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists not only help with glycemic control but also show renal-protective effects. SGLT2 inhibitors, in particular, have been shown to reduce the risk of kidney disease progression.

Blood Pressure Control

Hypertension is a key driver of DN progression. The latest guidelines recommend:

- Blood pressure target: For individuals with diabetic nephropathy, aim for a blood pressure of <130/80 mmHg.

- First-line agents: Angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) are recommended as first-line therapy in patients with diabetes and albuminuria, as they have been shown to reduce proteinuria and slow the progression of kidney disease.

Lifestyle Modifications

- Dietary changes: A low-sodium diet (<2,300 mg/day) is recommended to help control blood pressure. In some cases, a moderate reduction in protein intake (0.8 g/kg/day) may be suggested to slow disease progression.

- Weight management: Obesity is a risk factor for both diabetes and kidney disease. Weight loss can help improve glycemic control, blood pressure, and overall kidney health.

- Exercise: Regular physical activity can help control blood sugar levels, reduce blood pressure, and improve cardiovascular health.

SGLT2 Inhibitors and GLP-1 Receptor Agonists

Recent studies have shown that certain glucose-lowering agents have benefits beyond glycemic control, particularly in protecting kidney function:

- SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin): These drugs reduce hyperfiltration and proteinuria, slow eGFR decline, and reduce the risk of kidney failure and cardiovascular events.

- GLP-1 receptor agonists (e.g., liraglutide, semaglutide): These drugs have been shown to reduce the risk of cardiovascular events and may have renoprotective effects as well.

Management of Dyslipidemia

Controlling lipid levels is important in reducing cardiovascular risk in patients with diabetes and kidney disease. Statin therapy is generally recommended in patients

with diabetic nephropathy, especially those with additional cardiovascular risk factors.

- Statins: First-line treatment for dyslipidemia, aiming to achieve LDL cholesterol targets as recommended by guidelines.

5. Monitoring and Follow-Up

Patients with diabetic nephropathy should be closely monitored for changes in kidney function and albuminuria:

- Annual UACR and eGFR testing: Regular testing is essential to track the progression of kidney disease.

- Adjustment of medications: Drug dosages, particularly those for managing diabetes and blood pressure, may need to be adjusted as kidney function declines.

6. Preventive Strategies

Prevention of diabetic nephropathy in patients with diabetes involves:

- Early and aggressive blood sugar control to prevent the onset of microalbuminuria.

- Blood pressure management to prevent kidney damage.

- Use of renin-angiotensin system blockers (ACEIs or ARBs) in patients with albuminuria.

- Lifestyle modifications such as diet, exercise, and smoking cessation.

7. End-Stage Renal Disease (ESRD) Considerations

For patients with advanced diabetic nephropathy and ESRD, management options include:

- Dialysis: Either hemodialysis or peritoneal dialysis may be necessary once kidney function is severely impaired.

- Kidney transplantation: For eligible patients, kidney transplantation is the preferred option due to better long-term outcomes compared to dialysis.

Conclusion

Diabetic nephropathy remains a major complication of diabetes, but with early detection and adherence to the latest guidelines, its progression can be slowed or even halted. Management strategies focus on tight glucose control, blood pressure management, use of renoprotective medications like SGLT2 inhibitors, and lifestyle changes. Regular monitoring and individualized treatment plans are essential to improving outcomes and preventing ESRD.

[i] Andersen AR, Christiansen JS, Andersen JK, Kreiner S, Deckert T. Diabetic nephropathy in type 1 (insulin-dependent) diabetes: an epidemiological study. Diabetologia. 1983;25:496–501.

[ii] Tang SC, Chan GC, Lai KN. Recent advances in managing and understanding diabetic nephropathy. F1000Res. 2016. 5:[QxMD MEDLINE Link]. [Full Text].

[iii] Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney Int. 1995 Jun;47(6):1703–20. http://dx.doi.org/10.1038/ki.1995.236

[iv] Freedman BI, Spray BJ, Tuttle AB, Buckalew VM Jr. The familial risk of end-stage renal disease in African

Americans. Am J Kidney Dis. 1993 Apr;21(4):387–93. http://dx.doi.org/10.1016/S0272-6386(12)80266-6
[v] Stanton RC. Clinical challenges in diagnosis and management of diabetic kidney disease. Am J Kidney Dis. 2014 Feb;63(2 Suppl 2):S3–21. http://dx.doi.org/10.1053/j.ajkd.2013.10.050
[vi] Pavkov ME, Knowler WC, Bennett PH, Looker HC, Krakoff J, Nelson RG. Increasing incidence of proteinuria and declining incidence of end-stage renal disease in diabetic Pima Indians. Kidney Int. 2006 Nov;70(10):1840–6. http://dx.doi.org/10.1038/sj.ki.5001882
[vii] Wu AY, Kong NC, de Leon FA, Pan CY, Tai TY, Yeung VT, et al. An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: The MicroAlbuminuria Prevalence (MAP) Study. Diabetologia. 2005 Jan;48(1):17–26. http://dx.doi.org/10.1007/s00125-004-1599-9
[viii] Freedman BI, Volkova NV, Satko SG, Krisher J, Jurkovitz C, Soucie JM, et al. Population-based screening for family history of end-stage renal disease among incident dialysis patients. Am J Nephrol. 2005 Nov–Dec;25(6):529–35. http://dx.doi.org/10.1159/000088491
[ix] McClellan W, Speckman R, McClure L, Howard V, Campbell RC, Cushman M, et al. Prevalence and characteristics of a family history of end-stage renal disease among adults in the United States population: Reasons for Geographic and Racial Differences in Stroke (REGARDS) renal cohort study. J Am Soc Nephrol. 2007 Apr;18(4):1344–52. http://dx.doi.org/10.1681/ASN.2006090952